Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$45.29

-0.2 (-0.44%)

15:51
09/29/19
09/29
15:51
09/29/19
15:51

AstraZeneca presents OS results from Phase III FLAURA trial of TAGRISSO

AstraZeneca presented detailed overall survival results from the Phase III FLAURA trial of TAGRISSO in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for TAGRISSO versus gefitinib or erlotinib, both of which were previous standard-of-care treatments in this setting. TAGRISSO delivered a median OS of 38.6 months versus 31.8 months for the comparator arm. At three years, 28% of patients in the TAGRISSO arm and 9% of patients in the comparator arm remained on 1st-line study treatment. TAGRISSO also showed a statistically significant and clinically meaningful 52% reduction in the risk of central nervous system disease progression, increasing the time patients with CNS metastases lived without CNS disease progression or death. In the FLAURA trial, the safety and tolerability of TAGRISSO was consistent with its established profile. TAGRISSO was generally well tolerated, with Grade 3 or higher adverse events occurring in 42% of patients taking TAGRISSO versus 47% in the comparator arm. The FLAURA trial met its primary endpoint in July 2017, showing a statistically significant and clinically meaningful improvement in PFS, increasing the time patients lived without disease progression or death from any cause. TAGRISSO is currently approved in 78 countries, including the U.S., Japan, China and the EU, for 1st-line EGFR-mutated metastatic NSCLC.

  • 02

    Oct

AZN AstraZeneca
$45.29

-0.2 (-0.44%)

08/13/19
BOFA
08/13/19
DOWNGRADE
Target $7
BOFA
Neutral
Clovis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.
08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

RES

RPC, Inc.

$4.61

0.065 (1.43%)

06:21
10/21/19
10/21
06:21
10/21/19
06:21
Upgrade
RPC, Inc. rating change  »

RPC, Inc. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

GOLD

Barrick Gold

$17.20

0.095 (0.56%)

06:20
10/21/19
10/21
06:20
10/21/19
06:20
Hot Stocks
Barrick Gold preparing to restart gold mining in Tanzania »

The government of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:19
10/21/19
10/21
06:19
10/21/19
06:19
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTE

DTE Energy

$127.38

-2.11 (-1.63%)

06:19
10/21/19
10/21
06:19
10/21/19
06:19
Upgrade
DTE Energy rating change  »

DTE Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:19
10/21/19
10/21
06:19
10/21/19
06:19
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$67.62

-0.53 (-0.78%)

06:18
10/21/19
10/21
06:18
10/21/19
06:18
Periodicals
Exxon Mobil climate-change accounting case heads to court, WSJ reports »

Exxon Mobil Corp. and New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

COMM

CommScope

$11.56

-0.06 (-0.52%)

06:16
10/21/19
10/21
06:16
10/21/19
06:16
Upgrade
CommScope rating change  »

Nomura upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

  • 09

    Dec

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:16
10/21/19
10/21
06:16
10/21/19
06:16
Initiation
Peloton initiated  »

Peloton initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:16
10/21/19
10/21
06:16
10/21/19
06:16
Initiation
Peloton initiated  »

Peloton initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:14
10/21/19
10/21
06:14
10/21/19
06:14
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:14
10/21/19
10/21
06:14
10/21/19
06:14
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$15.36

0.16 (1.05%)

06:13
10/21/19
10/21
06:13
10/21/19
06:13
Upgrade
HP Enterprise rating change  »

HP Enterprise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 09

    Dec

CBS

CBS

$36.75

-1 (-2.65%)

, VIAB

Viacom

$22.05

-0.56 (-2.48%)

06:12
10/21/19
10/21
06:12
10/21/19
06:12
Recommendations
CBS, Viacom analyst commentary  »

Barclays cuts CBS target…

CBS

CBS

$36.75

-1 (-2.65%)

VIAB

Viacom

$22.05

-0.56 (-2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

SXT

Sensient

$60.17

-6.4 (-9.61%)

06:11
10/21/19
10/21
06:11
10/21/19
06:11
Downgrade
Sensient rating change  »

Sensient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:07
10/21/19
10/21
06:07
10/21/19
06:07
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPRT

Oportun Financial

$15.89

-0.22 (-1.37%)

06:06
10/21/19
10/21
06:06
10/21/19
06:06
Initiation
Oportun Financial initiated  »

Oportun Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$5.35

0.12 (2.29%)

06:06
10/21/19
10/21
06:06
10/21/19
06:06
Hot Stocks
Universal Technical CEO Kimberly McWaters to retire, Jerome Grant to succeed »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPE

Callon Petroleum

$3.83

-0.25 (-6.13%)

06:05
10/21/19
10/21
06:05
10/21/19
06:05
Hot Stocks
Callon Petroleum sees Q3 production 37.5-37.9 Mboed »

Callon Petroleum provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 14

    Nov

AXNX

Axonics

$20.43

0.01 (0.05%)

06:04
10/21/19
10/21
06:04
10/21/19
06:04
Initiation
Axonics initiated  »

Axonics initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

RUHN

Ruhnn

$4.90

0.4 (8.89%)

, RDVT

Red Violet

$14.38

-0.09 (-0.62%)

06:03
10/21/19
10/21
06:03
10/21/19
06:03
Hot Stocks
Ruhnn appoints Jacky Jinbo Wang as new CFO »

Ruhnn (RUHN) has…

RUHN

Ruhnn

$4.90

0.4 (8.89%)

RDVT

Red Violet

$14.38

-0.09 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTHR

United Therapeutics

$82.12

0.51 (0.62%)

06:03
10/21/19
10/21
06:03
10/21/19
06:03
Hot Stocks
United Therapeutics announces FDA approval of sNDA for Orenitram E-R Tablets »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADDYY

Adidas

$0.00

(0.00%)

06:02
10/21/19
10/21
06:02
10/21/19
06:02
Downgrade
Adidas rating change  »

Adidas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MTB

M&T Bank

$152.09

-0.01 (-0.01%)

06:01
10/21/19
10/21
06:01
10/21/19
06:01
Downgrade
M&T Bank rating change  »

M&T Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$119.15

-0.71 (-0.59%)

05:59
10/21/19
10/21
05:59
10/21/19
05:59
Periodicals
Walmart's Flipkart to enter food retail business in India, TechCrunch reports »

Flipkart, which sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

SPR

Spirit AeroSystems

$79.40

-3.49 (-4.21%)

, BA

Boeing

$344.09

-25.04 (-6.78%)

05:59
10/21/19
10/21
05:59
10/21/19
05:59
Downgrade
Spirit AeroSystems, Boeing rating change  »

Spirit AeroSystems…

SPR

Spirit AeroSystems

$79.40

-3.49 (-4.21%)

BA

Boeing

$344.09

-25.04 (-6.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.